OS Therapies Granted U.S. FDA Type C Statistical Methods Meeting to Review 2.5-Year Overall Survival Data for OST-HER2 in the Prevention or Delay of Recurrence in Fully Resected, Pulmonary Metastatic Osteosarcoma

RegulatoryOST-HER2Positive

AI Analysis

Summary

OS Therapies has been granted an FDA Type C Statistical Methods Meeting to review 2.5-year overall survival data for OST-HER2 in preventing or delaying recurrence of pulmonary metastatic osteosarcoma following complete resection.

Clinical Trial Data

Outcome Details

Type C Statistical Methods Meeting granted by FDA to review 2.5-year overall survival data

Importance:6/10

Sentiment:

0.60

FDAType C MeetingOsteosarcomaOverall SurvivalRegulatory

Related Companies

$OSTX

Read the original article

Published by yahoo_finance on August 13, 2026 12:45 PM

Read Original